Ipessentia

Recent Cases and Trends in US litigation

Partners: Taft Stettinius & Hollister LLP The webinar series bring together leading legal experts who will share the latest legal updates, decisions, and insights in live sessions over the week, ensuring you have the global perspective to stay ahead of the game. Webinar Date: 28th November 2023 | Timings: 9:30 am IST Agenda: Written description: […]

1 participant enrolled

Partners:

Taft Stettinius & Hollister LLP

The webinar series bring together leading legal experts who will share the latest legal updates, decisions, and insights in live sessions over the week, ensuring you have the global perspective to stay ahead of the game.

Webinar Date: 28th November 2023 | Timings: 9:30 am IST

Agenda:

Written description: SUPREME COURT RULING: Amgen Inc. et al. v. Sanofi et al.

Indefinite: Niazi Licensing Corp. v. St. Jude Medical S.C., Inc.

Anticipation and obviousness:

United Therapeutics Corporation v. Liquidia Technologies. (Treprostinil)

Sun Pharmaceutical Industries, Inc. v. Incyte Corporation. (Ruxolitinib)

Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (Tasimelteon)

Amgen Inc. v. Sandoz Inc. (Apremilast)

Idenix Pharmaceuticals LLC v. Gilead Sciences Inc.

Regents of the University of Minnesota v. Gilead Sciences, Inc.

Our Speaker:

Roshan P. Shrestha, Ph.D. (rshrestha@taftlaw.com)

Dr. Roshan Shrestha’s practice encompasses intellectual property law, including patent litigation, prosecution, and opinion work in the chemical, pharmaceutical, and electronic material arts.

Dr. Shrestha has broad litigation experience, including district court litigation, contested AIA proceedings, e.g., Reexamination and Inter Partes Review (IPR) at the Patent Trial and Appeal Board (PTAB) in the United States Patent and Trademark Office (USPTO), International Trade Commission (ITC), and appellate matters.

Before practicing law, Dr. Shrestha was a research scientist at Los Alamos National Laboratory in New Mexico, where his investigation of materials for hydrogen storage technology received several patents. He received his J.D. from Northwestern University School of Law and his Ph.D. from the University of North Carolina at Chapel Hill.

Dr. Shrestha has been recognized by numerous legal publications as one of the preeminent lawyers. He has been recognized as a Rising Star by Super Lawyers® since 2014, as Best Lawyers® since 2020 and as a Leading Lawyers® since 2017. He was also recognized as “Forty under 40” attorneys by Chicago Law Bulletin.

 

Stephen R. Auten (sauten@taftlaw.com)

Steve is head of Taft’s Pharmaceutical & Life Sciences Litigation practice area. He is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog “Hatch Waxman ANDA Litigation Forum” or HALF, which has over 14,000 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation, and biosimilar market opportunities. Steve is a member of Taft’s Executive Committee.

He is currently counsel to a number of leading generics, including those who are first-to-file with an ANDA with a Paragraph IV Certification, and thus eligible for 180-days of market exclusivity.  Though he has litigated scores of ANDA cases, his current cases include generic versions of the following products: ANGIOMAX (bivalirudin), AXIRON (testosterone), BELVIQ (lorcaserin), DALIRESP (roflumilast), ELIQUIS (apixaban), FANAPT (iloperidone), JEVTANA KIT (cabazitaxel), KYPROLIS (carfilzomib), POMALYST (pomalidomide), STIVARGA (regorafenib), TEFLARO (ceftaroline fosamil), VIIBRYD (vilazodone), XARELTO (rivaroxaban), and XELJANZ (tofacitinib).

1
Webinar on Recent Cases and Trends in US litigation

Be the first to add a review.

Please, login to leave a review